申请人:OPAL ONCOLOGY LTD
公开号:WO2019185882A1
公开(公告)日:2019-10-03
The invention provides compounds of the formula (1) or salts or tautomers thereof; wherein: Q is SO or SO2; n is 1 or 2; R1 is selected from hydrogen and a non-aromatic C1-6 hydrocarbon group; R2 and R3 are independently selected from hydrogen and a C1-6 hydrocarbon group; or R2 and R3 together with the carbon atom to which they are attached form a carbonyl group (C=O), a cyclopropane-1,1-diyl group or a cyclobutane-1,1-diyl group; or R together with R2 forms a C2-4 alkylene linker which is optionally substituted with one or more substituents selected from a C1-4 hydrocarbon group, halogen, hydroxy and amino; R4 and R5 are independently selected from hydrogen and a non-aromatic C1-6 hydrocarbon group; or R4 and R5 together with the carbon atom to which they are attached form a cyclopropane-1,1-diyl group or a cyclobutane-1,1-diyl group; and Ar1 is selected from phenyl, thiophenyl and furanyl,each being optionally substituted. The compounds are useful in medicine, for example in the treatment of diseases, such as cancers.
该发明提供了以下化合物的结构(1)或其盐或互变异构体;其中:Q为SO或SO2;n为1或2;R1选自氢和非芳香C1-6烃基;R2和R3独立选自氢和C1-6烃基;或R2和R3与它们连接的碳原子一起形成羰基(C=O)、环丙烷-1,1-二基基团或环丁烷-1,1-二基基团;或R和R2一起形成一个C2-4烷基亚链,该亚链可选择地取代一个或多个选自C1-4烃基、卤素、羟基和氨基的取代基;R4和R5独立选自氢和非芳香C1-6烃基;或R4和R5与它们连接的碳原子一起形成环丙烷-1,1-二基基团或环丁烷-1,1-二基基团;Ar1选自苯基、噻吩基和呋喃基,每个基可选择地取代。这些化合物在医学上有用,例如在治疗癌症等疾病方面。